Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Specific Antigen (PSA) testing in an underserved population before and after the United States Preventative Services Task Force (USPSTF) recommendation against screening. Methods: Data were collected on all PSA and cholesterol screening tests from 2008 to 2014. We examined the trend of these tests and prostate biopsies while comparing this data to lipid panel data to adjust for changes in patient population. Results: A decrease in PSA screening was observed from 2010 through 2014, with the greatest decline in 2012. The age group most affected was patients aged 55–69 years. The amount of prostate biopsies during this period decreased as well. Conclusi...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Specific...
Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Specific...
Background/Aims: Controversial clinical guidelines have recommended against widespread prostate-spec...
PURPOSE: This study describes longitudinal trends in the use of prostate-specific antigen (PSA)-base...
PURPOSE: This study describes longitudinal trends in the use of prostate-specific antigen (PSA)-base...
Purpose: To evaluate the impact that the 2012 US Preventive Services Task Force (USPSTF) prostate-sp...
INTRODUCTION: Limited data exist on trends in PSA screening in men with a family history of prostate...
© 2014 American Cancer Society. BACKGROUND: Prostate-specific antigen (PSA) screening for prostate c...
Purpose:To assess changes of prostate-specific antigen (PSA) testing following recent US Preventive ...
BackgroundProstate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagno...
Introduction: This study evaluates the potential impact of the publication of conflicting prostate c...
BackgroundProstate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagno...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Specific...
Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Specific...
Background/Aims: Controversial clinical guidelines have recommended against widespread prostate-spec...
PURPOSE: This study describes longitudinal trends in the use of prostate-specific antigen (PSA)-base...
PURPOSE: This study describes longitudinal trends in the use of prostate-specific antigen (PSA)-base...
Purpose: To evaluate the impact that the 2012 US Preventive Services Task Force (USPSTF) prostate-sp...
INTRODUCTION: Limited data exist on trends in PSA screening in men with a family history of prostate...
© 2014 American Cancer Society. BACKGROUND: Prostate-specific antigen (PSA) screening for prostate c...
Purpose:To assess changes of prostate-specific antigen (PSA) testing following recent US Preventive ...
BackgroundProstate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagno...
Introduction: This study evaluates the potential impact of the publication of conflicting prostate c...
BackgroundProstate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagno...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
OBJECTIVE: To evaluate state-by-state trends in prostate-specific antigen (PSA) screening prevalence...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...